Physician profile
Gary L Conrad
NPI 1669424271
$3,124.71
in general payments reported to CMS, 2019-2025
28 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,648 · 2020: $671 · 2021: $479 · 2022: $72.94 · 2023: $118 · 2024: $13.40 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $253.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $525.30 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $483.29 | 2019-2021 | |
| Pfizer INC. | $351.79 | 2019-2021 | |
| Abbott Laboratories | $225.51 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $205.93 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $196.50 | 2019-2021 | |
| Amarin Pharma, INC. | $180.93 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.60 | 2025 | |
| Sanofi-Aventis U.S. LLC | $104.16 | 2019 | |
| Medtronic Vascular, INC. | $100.12 | 2020 | |
| Esperion Therapeutics, INC. | $97.38 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $68.15 | 2019-2020 | |
| Akcea Therapeutics, INC. | $61.50 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $57.13 | 2019-2021 | |
| Cmp Pharma, INC. | $52.05 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.86 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $48.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $35.56 | 2019 | |
| Edwards Lifesciences Corporation | $33.46 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.51 | 2019 | |
| Boston Scientific Corporation | $24.15 | 2021 | |
| Gilead Sciences, INC. | $19.81 | 2019 | |
| Philips North America LLC | $14.76 | 2020 | |
| Irhythm Technologies, INC. | $14.65 | 2019 | |
| Tactile Systems Technology INC | $14.16 | 2020 | |
| Cleerly, INC. | $13.40 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Travere Therapeutics, INC. | $1.05 | 2020-2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Conrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.